Torsten Hoffmann

Chief Scientific Officer (CSO)

Dr. Hoffmann has more than 20 years of experience in the pharmaceutical and biotech industry sector. His roles included senior positions during 16 years at Roche, Chief Scientific Officer and Executive VP at Danish Zealand Pharma, Chief Scientific Officer at German Proteros biostructures, Chief Scientific Officer at UK based Silence Therapeutics and most recently SVP Drug Discovery at Taros Chemicals in Germany. He invented Netupitant, approved in the US as Akynzeo® for the treatment of chemotherapy-induced nausea and vomiting. Throughout his career he has successfully prioritized and advanced strong R&D portfolios and implemented novel approaches to encourage and enable innovation. He has also held several Scientific Advisory Board member roles in the European biotechnology industry and published more than 95 journal articles, patent applications, conference reports and public corporate events.